Show me a biotech CEO that is not talking about deals. It's a load of crock, most are way too early. Why is Campbell any different? Just got a hunch? I invest almost exclusively in biotech companies and I am happy to be sceptical about what the Companies I invest in and what they are saying, because they all pump the same lines - high unmet medical need, best in class, partnerships etc etc.
Reality is that a deal is much more likely further down the track than after GMP.
Show me a biotech CEO that is not talking about deals. It's a...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $1.336K | 167K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 8034700 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1996944 | 7 |
View Market Depth
| Last trade - 10.20am 24/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |